Quest Diagnostics Incorporated: 10-K Risk Factor Changes

2024 vs 2023  ·  SEC EDGAR  ·  2026-05-22
Other years: 2026 vs 2025 · 2025 vs 2024
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Quest Diagnostics added a new risk disclosure focused on artificial intelligence governance, reflecting management's assessment of AI-related business exposure in its testing services operations. Eight substantive modifications to existing risks suggest Quest recalibrated its risk narrative around debt flexibility, operational resilience to natural disasters and geopolitical events, and competitive positioning in clinical testing. The company maintained 17 unchanged risk factors while removing no previously disclosed risks, indicating a net expansion of disclosed risk areas year-over-year.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

1
New Risks
0
Removed
8
Modified
17
Unchanged
🟢 New in Current Filing We have been and expect to continue to use AI technology in the testing services we offer. The challenges with properly managing the development and use of these technological innovations could result in harm to our reputation, business or customers, and adversely affect our results of operations. 🔒
🟡 Modified Our outstanding debt may impair our financial and operating flexibility. 🔒
🟡 Modified Our operations may be adversely impacted by the effects of natural disasters such as hurricanes and earthquakes, public health emergencies and pandemics, geopolitical matters, hostilities or acts of terrorism and other criminal activities. 🔒
🟡 Modified The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability. 🔒
🟡 Modified The U.S. healthcare system continues to evolve, and medical laboratory testing market fundamentals are changing, and our business could be adversely impacted if we fail to adapt. 🔒
🟡 Modified Our ability to attract and retain qualified employees and maintain good relations with our employees is critical to the success of our business and the failure to do so may materially adversely affect our performance. 🔒
🟡 Modified Our business and operations could be adversely impacted by the FDA's approach to regulation. 🔒
🟡 Modified The development of new technologies is rapidly changing diagnostic testing, which will impact the healthcare industry and the competitive environment. The development of new, more cost-effective solutions that can be performed by our customers or by patients, which could accelerate the internalization of testing by hospitals or clinicians, could negatively impact our testing volume and revenues. 🔒
🟡 Modified Any future public health emergencies or pandemics may negatively affect us, including through its impact on the labor force and supply chain. 🔒
9 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →